SEC Contract Filing

Filing Date: 2025-02-27

Document Content:
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>2
<FILENAME>c4t-mkdgcollaborationagr.htm
<DESCRIPTION>EX-10.19
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>c4t-mkdgcollaborationagr</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:966;"><!-- c4t-mkdgcollaborationagr001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="c4t-mkdgcollaborationagr001.jpg" title="slide1" width="966" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">ACTIVE/128326788.11 Confidential Execution Copy Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark &#8220;[***]&#8221;. RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between C4 THERAPEUTICS, INC. and MERCK KGaA, Darmstadt, Germany </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- c4t-mkdgcollaborationagr002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="c4t-mkdgcollaborationagr002.jpg" title="slide2" width="966" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">ACTIVE/128326788.11 -i- TABLE OF CONTENTS Page 1. DEFINITIONS AND INTERPRETATIONS ................................................................1 2. LICENSES; EXCLUSIVITY ......................................................................................18 2.1. License to MKDG ............................................................................................18 2.2. License to C4T .................................................................................................18 2.3. [***]. .................................................................................................................18 2.4. No Implied Licenses ........................................................................................19 2.5. Exclusivity .......................................................................................................19 3. RESEARCH COLLABORATION ..............................................................................20 3.1. Collaboration Term ..........................................................................................20 3.2. Research Collaboration ....................................................................................21 3.3. MKDG Phase ...................................................................................................22 3.4. Work Plan ........................................................................................................22 3.5. R&amp;D Budget and Cost Allocation ...................................................................22 3.6. Conduct of Research Collaboration .................................................................23 3.7. Collaboration Targets.......................................................................................23 3.8. Technology Transfer ........................................................................................24 3.9. Virtual Data Room ...........................................................................................24 4. DEVELOPMENT AND COMMERCIALIZATION ..................................................24 4.1. Development ....................................................................................................24 4.2. Commercialization ...........................................................................................25 5. GOVERNANCE ..........................................................................................................25 5.1. Alliance Manager .............................................................................................25 5.2. Joint Research Committee ...............................................................................26 5.3. Joint Steering Committee .................................................................................27 5.4. JRC and JSC Decisions ....................................................................................27 5.5. Scope of JRC and JSC Authority .....................................................................28 6. FINANCIAL PROVISIONS .......................................................................................28 6.1. Upfront Fee ......................................................................................................28 6.2. R&amp;D Funding...................................................................................................28 6.3. [***] ..................................................................................................................28 6.4. Development and Commercialization Milestones Payments ..........................29 6.5. Calculation and Payment of Royalties .............................................................31 6.6. Payment Currency / Exchange Rate / Invoices ................................................33 6.7. Legal Restrictions ............................................................................................34 6.8. Late Payments ..................................................................................................34 6.9. Taxes ................................................................................................................34 6.10. Records and Audit Rights ................................................................................35 7. INTELLECTUAL PROPERTY RIGHTS ...................................................................36 7.1. Background IP .................................................................................................36 7.2. Ownership of Inventions ..................................................................................36 7.3. Patent Prosecution and Maintenance ...............................................................37 </FONT>